amifampridine
Nervous system (N07)US regulatory status: approved. Molecular target: Voltage-gated potassium channel.
- Target
- Voltage-gated potassium channel
- Mechanism
- Voltage-gated potassium channel blocker
pharma · Hemophilia A With Inhibitor · Hemophilia A · CPRX
CATALYST PHARMACEUTICALS
CATALYST PHARMACEUTICALS, INC.
CATALYST PHARMACEUTICALS drug portfolio — 20 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134, US HQ
2002 Founded
179 Employees
Public company Type
CPRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134, US
- Founded
- 2002
- Employees
- 179
- Programs
- 23
- Drugs
- 20
- Patents
- 61
CATALYST PHARMACEUTICALS pipeline
Portfolio lens on 20 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CATALYST PHARMACEUTICALS drug portfolio — 20 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Voltage-gated potassium channel.
- Target
- Voltage-gated potassium channel
- Mechanism
- Voltage-gated potassium channel blocker
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
aprocitentan
Cardiovascular system (C02)US regulatory status: approved. Molecular target: Endothelin receptor, ET-A/ET-B.
- Target
- Endothelin receptor, ET-A/ET-B
- Mechanism
- Endothelin receptor, ET-A/ET-B antagonist
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 1.
- Target
- Solute carrier family 12 member 1
- Mechanism
- Sodium-(potassium)-chloride cotransporter 2 inhibitor
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in CATALYST PHARMACEUTICALS's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
decitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 1 inhibitor
-
dupilumab
Dermatologicals (D11)US regulatory status: approved. Molecular target: Interleukin-4 receptor subunit alpha.
- Target
- Interleukin-4 receptor subunit alpha
- Mechanism
- Interleukin-4 receptor subunit alpha antagonist
-
eptacog alfa (activated)
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in CATALYST PHARMACEUTICALS's portfolio. Molecular target: Coagulation factor VII.
- Target
- Coagulation factor VII
- Mechanism
- Coagulation factor VII exogenous protein
-
fampridine
Nervous system (N07)Nervous system (N07) compound in CATALYST PHARMACEUTICALS's portfolio. Molecular target: Voltage-gated potassium channel.
- Target
- Voltage-gated potassium channel
- Mechanism
- Voltage-gated potassium channel blocker
-
human coagulation factor viii / human von willebrand factor
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in CATALYST PHARMACEUTICALS's portfolio.
-
Development asset linked to CATALYST PHARMACEUTICALS in public FDA and regional records.
-
nonacog alfa
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in CATALYST PHARMACEUTICALS's portfolio. Molecular target: Coagulation factor IX.
- Target
- Coagulation factor IX
- Mechanism
- Coagulation factor IX exogenous protein
-
US regulatory status: approved. Molecular target: Copper.
- Target
- Copper
- Mechanism
- Copper chelating agent
-
Development asset linked to CATALYST PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to CATALYST PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to CATALYST PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
vamorolone
Systemic hormonal preparations (H02)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Mineralocorticoid receptor antagonist
-
vigabatrin
Nervous system (N03)US regulatory status: approved. Molecular target: 4-aminobutyrate aminotransferase, mitochondrial.
- Target
- 4-aminobutyrate aminotransferase, mitochondrial
- Mechanism
- Gamma-amino-N-butyrate transaminase inhibitor